ACCELERON PHARMA INC Contracts & Agreements
77 Contracts & Agreements
- Business Finance (22 contracts)
- Business Operations (6)
- Human Resources (34)
- Intellectual Property (2)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (10)
- Amendment to the Employment Agreement between Habib Dable and Acceleron Pharma Inc., dated as of September 29, 2021 (Filed With SEC on November 4, 2021)
- Amendment to the Employment Agreement between Jay Backstrom and Acceleron Pharma Inc., dated as of September 29, 2021 (Filed With SEC on November 4, 2021)
- Amendment to the Employment Agreement between Sujay Kango and Acceleron Pharma Inc., dated as of September 29, 2021 (Filed With SEC on November 4, 2021)
- Amendment to the Employment Agreement between Kevin McLaughlin and Acceleron Pharma Inc., dated as of September 29, 2021 (Filed With SEC on November 4, 2021)
- Amendment to the Employment Agreement between Adam Veness and Acceleron Pharma Inc., dated as of September 29, 2021 (Filed With SEC on November 4, 2021)
- Agreement and Plan of Merger, dated as of September 29, 2021, by and among Acceleron Pharma Inc., Merck Sharp & Dohme Corp. and Astros Merger Sub, Inc (Filed With SEC on September 30, 2021)
- Collaboration, License and Option Agreement between Acceleron Pharma Inc. and Celgene Corporation, dated as of August 2, 2011 (Filed With SEC on August 5, 2021)
- Employment Agreement between Adam M. Veness, Esq. and Acceleron Pharma Inc., dated as of June 5, 2019 (Filed With SEC on February 25, 2021)
- Offer Letter between Jay T. Backstrom, M.D., M.P.H. and Acceleron Pharma Inc., dated as of December 4, 2019 (Filed With SEC on February 25, 2021)
- Employment Agreement between Jay T. Backstrom, M.D., M.P.H. and Acceleron Pharma Inc., dated as of December 10, 2019 (Filed With SEC on February 25, 2021)
- Form of Non-Statutory Stock Option Agreement for Company Employees under the 2013 Equity Incentive Plan (Filed With SEC on February 25, 2021)
- Form of Non-Statutory Stock Option Agreement for Non-Employee Directors under the 2013 Equity Incentive Plan (Filed With SEC on February 25, 2021)
- Form of Restricted Stock Unit Award Agreement for Company Employees under the 2013 Equity Incentive Plan (Filed With SEC on February 25, 2021)
- Form of Restricted Stock Unit Award Agreement for Non-Employee Directors under the 2013 Equity Incentive Plan (Filed With SEC on February 25, 2021)
- Form of Performance-Based Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan (Filed With SEC on February 25, 2021)
- Underwriting Agreement, dated June 30, 2020, by and among the Company and the Representatives (Filed With SEC on July 2, 2020)
- Letter Agreement to Amended and Restated Collaboration, License and Option Agreement between Acceleron Pharma Inc. and Celgene Corporation, dated as of March 10, 2020 (Filed With SEC on May 11, 2020)
- Description of Capital Stock (Filed With SEC on February 27, 2020)
- Form of Non-Statutory Stock Option Agreement under the 2013 Equity Incentive Plan (Filed With SEC on February 27, 2020)
- Form of Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan (Filed With SEC on February 27, 2020)
- Form of Performance-Based Restricted Stock Unit Award Agreement under the 2013 Equity Incentive Plan (Filed With SEC on February 27, 2020)
- Offer Letter between Sujay Kango and Acceleron Pharma Inc., dated as of December 29, 2017 (Filed With SEC on February 27, 2019)
- Employment Agreement between Sujay Kango and Acceleron Pharma Inc., dated as of February 12, 2018 (Filed With SEC on February 27, 2019)
- Offer Letter between Robert K. Zeldin and Acceleron Pharma Inc., dated as of June 15, 2018 (Filed With SEC on February 27, 2019)
- Employment Agreement between Robert K. Zeldin and Acceleron Pharma Inc., dated as of June 29, 2018 (Filed With SEC on February 27, 2019)
- Underwriting Agreement, dated January 15, 2019, by and among the Company and the Representatives (Filed With SEC on January 17, 2019)
- Collaboration, License and Option Agreement between Acceleron Pharma Inc. and Celgene Corporation, dated as of August 2, 2011 (Filed With SEC on August 2, 2018)
- Separation and Transition Agreement, by and between Matthew L. Sherman and Acceleron Pharma Inc., dated as of January 2, 2018 (Filed With SEC on January 3, 2018)
- Amended and Restated Collaboration, License and Option Agreement between Acceleron Pharma Inc. and Celgene Corporation, dated as of September 18, 2017 (Filed With SEC on November 7, 2017)
- Underwriting Agreement, dated January 5, 2016, by and among the Company and the Representatives (Filed With SEC on September 25, 2017)
- FIRST AMENDMENT TO LEASE (Filed With SEC on July 19, 2017)
- AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on May 2, 2017)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on March 1, 2017)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on March 1, 2017)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on March 1, 2017)
- Name:[]Number of Restricted Stock Units subject to Award:[]Date of Grant:[] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on March 1, 2017)
- EXHIBIT A ACCELERON PHARMA INC. PERSONNEL VESTING SUMMARY AS OF DECEMBER 1, 2016 JOHN L. KNOPF (Filed With SEC on November 3, 2016)
- [Rest of page intentionally left blank.] (Filed With SEC on September 27, 2016)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on August 4, 2016)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST.REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on August 4, 2016)
- ACCELERON PHARMA INC. SHORT-TERM INCENTIVE COMPENSATION PLAN (Filed With SEC on June 6, 2016)
- Name:[]Number of Restricted Stock Units subject to Award:[]Date of Grant:[] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on February 25, 2016)
- 3,750,000 SHARES ACCELERON PHARMA INC. COMMON STOCK ($0.001 PAR VALUE) UNDERWRITING AGREEMENT January 5, 2016 (Filed With SEC on January 11, 2016)
- FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on September 11, 2015)
- FIRST AMENDMENT TO THE AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on September 11, 2015)
- Name:[]Number of Restricted Stock Units subject to Award:[]Date of Grant:[] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on September 11, 2015)
- Name:[]Number of Restricted Stock Units subject to Award:[]Date of Grant:[] ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on March 2, 2015)
- ACTRIIB AMENDMENT (Filed With SEC on August 12, 2014)
- Acceleron Pharma Inc. [] Shares (1) Common Stock ($0.001 par value) Underwriting Agreement (Filed With SEC on January 21, 2014)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on January 21, 2014)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on January 21, 2014)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN NON-STATUTORY STOCK OPTION AGREEMENT (Filed With SEC on January 9, 2014)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT (Filed With SEC on January 9, 2014)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on September 24, 2013)
- Acceleron Pharma Inc. [ ] Shares (1) Common Stock ($0.001 par value) Underwriting Agreement (Filed With SEC on September 6, 2013)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on September 6, 2013)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on September 6, 2013)
- ACCELERON PHARMA INC. 2013 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on September 6, 2013)
- ACCELERON PHARMA INC. 2013 EQUITY INCENTIVE PLAN (Filed With SEC on August 20, 2013)
- ACCELERON PHARMA INC. CASH INCENTIVE PLAN (Filed With SEC on August 20, 2013)
- REGISTRATION RIGHTS AGREEMENT (AMENDED AND RESTATED AS OF [ ], 2013) (Filed With SEC on August 7, 2013)
- WARRANT TO PURCHASE STOCK (Filed With SEC on August 7, 2013)
- COMMON STOCK WARRANT CERTIFICATE (Filed With SEC on August 7, 2013)
- FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on August 7, 2013)
- VOTING AGREEMENT (AMENDED AND RESTATED AS OF [ ], 2013) (Filed With SEC on August 7, 2013)
- RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (AMENDED AND RESTATED AS OF DECEMBER 22, 2011) (Filed With SEC on August 7, 2013)
- INVESTOR RIGHTS AGREEMENT (AMENDED AND RESTATED AS OF DECEMBER 22, 2011) (Filed With SEC on August 7, 2013)
- LOAN AND SECURITY AGREEMENT (Filed With SEC on August 7, 2013)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on August 7, 2013)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on August 7, 2013)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on August 7, 2013)
- THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES... (Filed With SEC on August 7, 2013)
- EXCLUSIVE LICENSE AGREEMENT BETWEEN SALK INSTITUTE FOR BIOLOGICAL STUDIES AND ACCELERON PHARMA INC. ACTIVIN RECEPTORS (TYPE IIA) AND RELATED SUBJECT MATTER FOR THERAPEUTIC AND... (Filed With SEC on August 7, 2013)
- EXCLUSIVE LICENSE AGREEMENT BETWEEN SALK INSTITUTE FOR BIOLOGICAL STUDIES AND ACCELERON PHARMA INC. ACTIVIN RECEPTORS (TYPE IIB) AND RELATED SUBJECT MATTER FOR THERAPEUTIC AND... (Filed With SEC on August 7, 2013)
- 128 SIDNEY STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET (Filed With SEC on August 7, 2013)
- ACCELERON PHARMA INC. 2003 STOCK OPTION AND RESTRICTED STOCK PLAN (Filed With SEC on August 7, 2013)
- AMENDMENT TO SECURED PROMISSORY NOTE (Filed With SEC on August 7, 2013)